Menzies-Gow, Andrew
Hoyte, Flavia L.
Price, David B.
Cohen, David
Barker, Peter
Kreindler, James
Jison, Maria
Brooks, Christopher L.
Papeleu, Peggy
Katial, Rohit
Clinical trials referenced in this document:
Documents that mention this clinical trial
Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab
https://doi.org/10.1007/s12325-022-02098-1
S117 Clinical remission in patients with severe eosinophilic asthma: an analysis of SIROCCO and CALIMA trial data
https://doi.org/10.1136/thorax-2023-btsabstracts.123
P68 Asthma symptom improvements with benralizumab are associated with improvements in activity functions and quality of life for patients with severe, uncontrolled asthma: results of pooled phase iii benralizumab studies
https://doi.org/10.1136/thoraxjnl-2017-210983.210
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
https://doi.org/10.1016/s0140-6736(16)31324-1
Documents that mention this clinical trial
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
https://doi.org/10.1016/s0140-6736(16)31322-8
Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab
https://doi.org/10.1007/s12325-022-02098-1
S117 Clinical remission in patients with severe eosinophilic asthma: an analysis of SIROCCO and CALIMA trial data
https://doi.org/10.1136/thorax-2023-btsabstracts.123
P68 Asthma symptom improvements with benralizumab are associated with improvements in activity functions and quality of life for patients with severe, uncontrolled asthma: results of pooled phase iii benralizumab studies
https://doi.org/10.1136/thoraxjnl-2017-210983.210
Documents that mention this clinical trial
Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab
https://doi.org/10.1007/s12325-022-02098-1
Funding for this research was provided by:
AstraZeneca Schweiz
Article History
Received: 1 February 2022
Accepted: 18 February 2022
First Online: 14 March 2022
Change Date: 19 June 2022
Change Type: Update
Change Details: A peer-reviewed video abstract was retrospectively added to this publication.